Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles matching "interstitial lung disease"

Clinical trialRSSYesterday

Adding LAM-001 inhaled therapy leads to broad benefits for PH

Researchers tested a new inhaled medicine called LAM-001 on patients with two types of lung disease: pulmonary hypertension combined with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). All patients who finished the small early-stage trial showed significant improvement in their symptoms. The results are encouraging enough that the company plans to continue testing this medicine.

WHY IT MATTERSIf LAM-001 proves effective in larger trials, it could offer a new treatment option for PH-ILD patients, a condition with limited approved therapies that causes progressive breathing difficulty and high pressure in lung blood vessels.
👁 Watch this spacepulmonary hypertension with interstitial lung diseasepulmonary arterial hypertension
🔴 BreakingDrug approvalEMAYesterday

New medicine for two types of pulmonary fibrosis

The European Medicines Agency has approved a new medicine called Jascayd (nerandomilast) to treat adults with two types of lung scarring diseases: idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. This approval means the medicine is now available for patients in the European Union. This is the first time this particular medicine has been approved for these conditions in Europe.

WHY IT MATTERSPatients with idiopathic pulmonary fibrosis in the EU now have access to a newly approved treatment option that may help slow lung scarring and preserve breathing ability.
💬 Ask your doctoridiopathic pulmonary fibrosisprogressive fibrosing interstitial lung disease
ResearchPUBMEDApr 22

Linear Interstitial Keratitis - A Retrospective Chart Review of a Rare Entity.

Linear interstitial keratitis (LIK) is a very rare eye condition where a thin line of cloudiness forms in the clear part of the eye (the cornea). This study looked at 6 patients with this condition to better understand what it looks like, how doctors can diagnose it, and what treatments work best. The researchers found that the cloudy line usually appears near the edge of the cornea and can be seen clearly with special eye imaging tools.

WHY IT MATTERSThis is the largest study to date on linear interstitial keratitis, providing eye doctors with new guidance on diagnosis and treatment options for a condition that previously had no agreed-upon management approach.
💬 Ask your doctorLinear Interstitial KeratitisInterstitial Keratitis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases